Navigation Links
Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results
Date:8/1/2014

HYDERABAD, India, Aug. 1, 2014 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BSE-Scrip Code:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year (FY) 2015, ended June 30, 2014.

"Neuland's results in the first quarter were affected by work flow re-prioritization to accommodate certain customer needs, and we do not expect this to impact our overall performance for the new fiscal year," said Dr. D.R. Rao, Chairman and Managing Director of Neuland Labs. "We are now back to our regular schedule and expect to achieve the planned growth in revenues and profits for the year."

Revenues for the first quarter of FY 2015 were $17.10 million (1.03 billion INR*), compared to revenues in the first quarter of FY 2014 of $20.27 million (1.21 billion INR), a decrease of 15%.

Neuland reported EBITDA of $2.38 million (143.4 million INR) in the first quarter of FY 2015, compared to EBITDA of $3.45 million (206.0 million INR) in the comparable period in FY 2014, a decrease of 30%.

After-tax profits in the first quarter of FY 2015 were $0.49 million (30.25 million INR), compared to after-tax profits of $1.31 million (78.11 million INR) in the first quarter of FY 2014, a decrease of 61%.

Sucheth R. Davuluri, Chief Executive Officer of Neuland Labs, noted, "Our Company received SEBI approval for its proposed Rights Offering on July 10, 2014.,The Issue will provide us with additional capital to support the robust growth we are expecting during the remain
'/>"/>

SOURCE Neuland Laboratories Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuland Labs Reports Financial Results For Fiscal Year 2012
2. Neuland Labs Reports First Quarter Fiscal Year 2013 Financial Results
3. Neuland Labs Reports Second Quarter Fiscal Year 2013 Financial Results
4. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
5. Neuland Labs Reports Financial Results For Fiscal Year 2013
6. Neuland Labs Reports First Quarter Fiscal Year 2014 Financial Results
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
11. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014 Imprimis ... pharmaceutical company dedicated to delivering high quality and novel ... announced that Chief Executive Officer Mark Baum ... Annual Craig-Hallum Alpha Select Conference in New York City.  ... its Go Dropless™ campaign in ophthalmology. The presentation ...
(Date:9/16/2014)... -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing ... today that it has entered into an agreement with ... of animal studies for levorphanol, the active ingredient of ... levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC is the ... Pasternak said, "Levorphanol is a unique opioid analgesic that ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... COLLEGEVILLE, Pa., May 30 Wyeth,Pharmaceuticals, a ... today announced the,initiation of the INTORACT (INvestigation ... worldwide randomized, open-label, phase 3b,study comparing TORISEL(R) ... for first-line treatment of patients,with advanced renal ...
... evaluation of safety and tolerability, as ... 2 trials -, ROCKVILLE, Md., May 30 ... that it has initiated dosing in a Phase,1 clinical ... lead IAP,inhibitor, HGS1029, as monotherapy in patients with advanced ...
Cached Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 2Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 3Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 4
(Date:9/16/2014)... Francisco, September 15, 2014A prospective study that compared ... patients with bone metastases demonstrates that single fraction ... multiple fraction radiation therapy (MFRT) when pain, function ... research presented today at the American Society for ... study indicates that improvements in patients, pain, function ...
(Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Beginning October ... adding a new service offering for its clients who book ... to the volume of business they buy. Most recurring ... during the work week, but others include clients whose ... pet sitter on a daily basis. The ...
(Date:9/16/2014)... Founded by former Miami Beach mayoral candidate Steve ... fighting to legalize medical marijuana in Florida. Advocating for ... recently commissioned a shot-for-shot parody video of the song ... “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called “You’re the Law ... faithfully recreates the carnival scene made famous by John ...
(Date:9/16/2014)... Florida Hospital announced today it is teaming ... partnership and become the Presenting Sponsor of the 2014-15 ... health and wellness partner. As the Presenting Sponsor for ... logo and name inclusion on all Lightning advertising campaigns ... has been a sponsorship partner of the Lightning since ...
(Date:9/16/2014)... reduce the risk of heart disease or stroke, even ... part of the diet. , A study of ... from Monash University,s Department of Epidemiology and Preventive Medicine ... consumption of dairy foods had played in the country,s ... dominantly Chinese food culture, unaccustomed to dairy foods, consuming ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2
... Large study suggests the procedure impairs healthy immune response ... by Caesarean section are at increased risk of asthma, ... the respiratory health of nearly 3,000 infants. , By ... percent) of the children had been diagnosed with asthma ...
... the year. , ... (PRWEB) November 2, 2009 -- For the ... treatment Frontline , to UK mainland addresses, excluding the highlands and islands, ... the Hyperdrug.co.uk web site. , , ,Hyperdrug director Ben Watson says "Hyperdrug ...
... INDIANAPOLIS, Dec. 3 Vertellus Specialties Inc., a leading specialty ... January 1, 2009 for 2-vinylpyridine monomer sales to all non-contract ... investment in production capacity and to provide better supply chain ... About Vertellus Specialties Inc. ...
... positive airway pressure (CPAP) treatment seems to improve cognitive ... from obstructive sleep apnea, according to the results of ... California, San Diego. The study led by Sonia ... Diego School of Medicine and one of the nation,s ...
... the availability of Trade Alerts on stocks making news today. , ... notes for free by visiting: http://www.BeaconEquity.com/m , , ... ), Williams-Sonoma Inc. (NYSE: WSM ), Medicis Pharmaceutical Corp. (NYSE: ... Group Co. (Nasdaq: MHGC ) and DSP Group Inc. (Nasdaq: ...
... the body to selectively suppress the immune response may ... to scientists. , "If you like, what we are ... more like a fetus," said Dr. Andrew L. Mellor, ... and Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics. ...
Cached Medicine News:Health News:C-Section Might Boost Baby's Asthma Risk 2Health News:Beating the Credit Crunch with Hyperdrug.co.uk 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 3Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: SPC, WSM, MRX, WXS, MHGC, DSPG 2Health News:New approaches to protecting transplanted organs make first steps toward patients 2Health News:New approaches to protecting transplanted organs make first steps toward patients 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: